vimarsana.com
Home
Live Updates
Krazati Approved for KRASG12C-Mutated Locally Advanced or Me
Krazati Approved for KRASG12C-Mutated Locally Advanced or Me
Krazati Approved for KRASG12C-Mutated Locally Advanced or Metastatic NSCLC
The FDA has approved Krazati (adagrasib) for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Related Keywords
,
Drug Administration ,
Mirati Therapeutics Inc ,
Agilent Resolution ,